BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Deals

  Biopharma Executive Perspectives on 2022

  BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.

  January 8, 2022

   · 

  11 min read

   · 

  Heather McKenzie
• Pharm Country

  COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

  Ocugen, Inc. announced that its partner, Bharat Biotech, posted positive results from a Phase 2 analysis of the vaccine candidate, COVAXIN™, in participants ages 12-64, receiving a booster dose six months following a second dose on the pre-print server, medRxiv.

  January 8, 2022

   · 

  9 min read
• CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China

  CanSino Biologics Inc. announced that the National Medical Products Administration of China granted approval for its ACYW135 Meningococcal Conjugate Vaccine, making it the first of its kind to be authorized in China.

  January 8, 2022

   · 

  3 min read